# US 2025/0082650 A1 · Combined use of multikinase inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082650 A1
- Document ID: US20250082650A1
- Status: Published application
- Kind: A1
- Application number: 18/552,878
- Filed: 2022-03-29
- Published: 2025-03-13
- Earliest claimed: 2021-03-29
- Assignees: Transthera Sciences (Nanjing), Inc.
- Applicants: Transthera Sciences (Nanjing), Inc.
- Inventors: Peng PENG; Xiaoyan QIANG; Frank WU
- Web page: https://patentgrep.com/patent/US20250082650A1

## CPC

- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a pharmaceutical composition of a compound as shown in formula (I) or a pharmaceutically acceptable salt, a stereoisomer, or a crystal form thereof with a programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1) antibody, and a kit thereof and the use thereof in the treatment of cancer diseases, wherein Y, P, W and Ar are as defined in the specification.

## Claims

### Claim 1

A pharmaceutical composition of a multi-kinase inhibitor compound shown in formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a crystal form thereof and a programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1) antibody,
wherein,
Ar is selected from phenyl and 5-6 membered heteroaryl, Ar can be optionally substituted with 1 to 3 R6, and each R6 is independently selected from hydrogen, amino, cyano, halogen, C1-4 alkyl, trifluoromethyl, and methanesulfonyl;
Y is selected from CR3; P is selected from CR4; W is selected from N;
R3 is selected from hydrogen and C1-4 alkyl;
R4 is selected from hydrogen, hydroxyl, amino, carboxyl, cyano, nitro, halogen, C1-4 alkoxy, C3-6 cycloalkyloxy, oxa-C5-8 cycloalkyloxy, halogenated C1-4 alkoxy, C3-6 cycloalkylamino, C1-4 alkylsulfonyl, C3-6 cycloalkylsulfonyl, C1-4 alkylcarbonyl, C3-6 cycloalkylcarbonyl, —(CH2)n—C3-10 cycloalkyl, —(CH2)n-(5-11) membered heterocyclyl, and —(CH2)n-(5-10) membered heteroaryl, wherein n=0-6, a ring-forming S atom in the cycloalkyl, heterocyclyl, and heteroaryl can be optionally oxidized to S(O) or S(O)2, a ring-forming C atom in the cycloalkyl, heterocyclyl, and heteroaryl can be optionally oxidized to C(O), and the cycloalkyl, heteroaryl, and heterocyclyl can be optionally substituted with one or more substituents independently selected from C1-3 alkyl and C3-6 cycloalkyl.

### Claim 2

A kit for treating a cancer, comprising (a) a multi-kinase inhibitor compound shown in formula (I) or a pharmaceutically acceptable salt, a stereoisomer or a crystal form thereof, (b) a programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1) antibody, and (c) a package insert,
wherein,
Ar is selected from phenyl and 5-6 membered heteroaryl, Ar can be optionally substituted with 1 to 3 R6, and each R6 is independently selected from hydrogen, amino, cyano, halogen, C1-4 alkyl, trifluoromethyl, and methanesulfonyl;
Y is selected from CR3; P is selected from CR4; W is selected from N;
R3 is selected from hydrogen and C1-4 alkyl;
R4 is selected from hydrogen, hydroxyl, amino, carboxyl, cyano, nitro, halogen, C1-4 alkoxy, C3-6 cycloalkyloxy, oxa-C5-8 cycloalkyloxy, halogenated C1-4 alkoxy, C3-6 cycloalkylamino, C1-4 alkylsulfonyl, C3-6 cycloalkylsulfonyl, C1-4 alkylcarbonyl, C3-6 cycloalkylcarbonyl, —(CH2)n—C3-10 cycloalkyl, —(CH2)n-(5-11) membered heterocyclyl, and —(CH2)n-(5-10) membered heteroaryl, wherein n=0-6, a ring-forming S atom in the cycloalkyl, heterocyclyl, and heteroaryl can be optionally oxidized to S(O) or S(O)2, a ring-forming C atom in the cycloalkyl, heterocyclyl, and heteroaryl can be optionally oxidized to C(O), and the cycloalkyl, heteroaryl, and heterocyclyl can be optionally substituted with one or more substituents independently selected from C1-3 alkyl and C3-6 cycloalkyl.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein in the compound of formula (I):
Ar is selected from phenyl, Ar can be optionally substituted with 1 to 3 R6, and each R6 is independently selected from hydrogen, amino, cyano, halogen, C1-4 alkyl, trifluoromethyl, and methanesulfonyl;
Y is selected from CR3; P is selected from CR4; W is selected from N;
R3 is selected from hydrogen and C1-4 alkyl;
R4 is selected from hydrogen, hydroxyl, amino, carboxyl, cyano, nitro, halogen, C1-4 alkoxy, C3-6 cycloalkyloxy, halogenated C1-4 alkoxy, C3-6 cycloalkylamino, C1-4 alkylsulfonyl, C1-4 alkylcarbonyl, C3-6 cycloalkyl-carbonyl, —(CH2)n—C3-6 cycloalkyl, —(CH2)n-(5-6) membered monocyclic heterocyclyl, —(CH2)n-(7-11) membered fused heterocyclyl, —(CH2)n-(5-6) membered monocyclic heteroaryl, and —(CH2)n-(8-10) membered fused heteroaryl, wherein n=0-6, a ring-forming S atom in the cycloalkyl, heterocyclyl, and heteroaryl can be optionally oxidized to S(O) or S(O)2, a ring-forming C atom in the cycloalkyl, heterocyclyl, and heteroaryl can be optionally oxidized to C(O), and the cycloalkyl, heteroaryl, and heterocyclyl can be optionally substituted with one or more substituents independently selected from C1-3 alkyl and C3-6 cycloalkyl.

### Claim 4 (depends on 3)

The pharmaceutical composition according to claim 3, wherein formula (I) is selected from compounds with the following structures:

### Claim 5 (depends on 4)

The pharmaceutical composition according to claim 4, wherein formula (I) is selected from a compound with the following structure:

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1) antibody is a monoclonal antibody.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition can further comprise an additional anti-cancer agent or immunosuppressant.

### Claim 8 (depends on 1)

A method for preventing and/or treating a cancer mediated by multi-kinase abnormalities, which comprises administering to a subject the pharmaceutical composition according to claim 1, wherein the cancer comprises lung cancer, squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, breast cancer, head and neck cancer, endometrial cancer, corpus uteri cancer, rectal cancer, liver cancer, cholangiocarcinoma, gallbladder carcinoma, pancreatic cancer, renal cancer, renal pelvis cancer, esophageal cancer, esophageal adenocarcinoma, glioma, thyroid cancer, female reproductive system cancer, neurofibromatosis, bone cancer, skin cancer, brain cancer, colon cancer, testicular cancer, oral cancer, pharyngeal cancer, hematological cancer, villous adenoma of large intestine, melanoma, cytoma, and sarcoma.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the multi-kinase inhibitor compound shown in formula (I) and the programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1) antibody can be used in combination in a single formulation or administered to a patient as independent agents simultaneously, sequentially, or intermittently.

### Claim 10 (depends on 2)

The kit according to claim 2, wherein in the compound of formula (I):
Ar is selected from phenyl, Ar can be optionally substituted with 1 to 3 R6, and each R6 is independently selected from hydrogen, amino, cyano, halogen, C1-4 alkyl, trifluoromethyl, and methanesulfonyl;
Y is selected from CR3; P is selected from CR4; W is selected from N;
R3 is selected from hydrogen and C1-4 alkyl;
R4 is selected from hydrogen, hydroxyl, amino, carboxyl, cyano, nitro, halogen, C1-4 alkoxy, C3-6 cycloalkyloxy, halogenated C1-4 alkoxy, C3-6 cycloalkylamino, C1-4 alkylsulfonyl, C1-4 alkylcarbonyl, C3-6 cycloalkyl-carbonyl, —(CH2)n—C3-6 cycloalkyl, —(CH2)n-(5-6) membered monocyclic heterocyclyl, —(CH2)n-(7-11) membered fused heterocyclyl, —(CH2)n-(5-6) membered monocyclic heteroaryl, and —(CH2)n-(8-10) membered fused heteroaryl, wherein n=0-6, a ring-forming S atom in the cycloalkyl, heterocyclyl, and heteroaryl can be optionally oxidized to S(O) or S(O)2, a ring-forming C atom in the cycloalkyl, heterocyclyl, and heteroaryl can be optionally oxidized to C(O), and the cycloalkyl, heteroaryl, and heterocyclyl can be optionally substituted with one or more substituents independently selected from C1-3 alkyl and C3-6 cycloalkyl.

### Claim 11 (depends on 10)

The kit according to claim 10, wherein formula (I) is selected from compounds with the following structures:

### Claim 12 (depends on 11)

The kit according to claim 11, wherein formula (I) is selected from a compound with the following structure:

### Claim 13 (depends on 2)

The kit according to claim 2, wherein the programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1) antibody is a monoclonal antibody.

### Claim 14 (depends on 2)

The kit according to claim 2, wherein the kit can further comprise an additional anti-cancer agent or immunosuppressant.

### Claim 15 (depends on 2)

A method for preventing and/or treating a cancer mediated by multi-kinase abnormalities, which comprises administering to a subject the kit according to claim 2, wherein the cancer comprises lung cancer, squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, breast cancer, head and neck cancer, endometrial cancer, corpus uteri cancer, rectal cancer, liver cancer, cholangiocarcinoma, gallbladder carcinoma, pancreatic cancer, renal cancer, renal pelvis cancer, esophageal cancer, esophageal adenocarcinoma, glioma, thyroid cancer, female reproductive system cancer, neurofibromatosis, bone cancer, skin cancer, brain cancer, colon cancer, testicular cancer, oral cancer, pharyngeal cancer, hematological cancer, villous adenoma of large intestine, melanoma, cytoma, and sarcoma.

### Claim 16 (depends on 15)

The use according to claim 15, wherein the multi-kinase inhibitor compound shown in formula (I) and the programmed cell death protein 1/programmed cell death protein 1 ligand 1 (PD-1/PD-L1) antibody can be used in combination in a single formulation or administered to a patient as independent agents simultaneously, sequentially, or intermittently.
